New pill for macular degeneration enters early human testing
NCT ID NCT07330674
First seen Jan 09, 2026 · Last updated May 07, 2026 · Updated 16 times
Summary
This early-stage study tests an oral drug called ABF-101 in healthy adults and people with age-related macular degeneration (AMD). The main goal is to check safety and how the body processes the drug. If safe, it may help ease symptoms of AMD, a common cause of vision loss in older adults.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION (ARMD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dallas Clinical Research Unit
RECRUITINGDallas, Texas, 75247, United States
Contact
Conditions
Explore the condition pages connected to this study.